Therapy was NRX Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $3.42M of $4.90M (70%).
| Product and Service | FY 2025 |
|---|---|
| Therapy | $3.42M |
| Procedures | $1.48M |
| Total | $4.90M |
NRX Pharmaceuticals brought in $4.90M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Therapy was the largest at $3.42M (69.7%), ahead of Procedures at $1.48M (30.3%).
Commercial Insurance was NRX Pharmaceuticals’s largest revenue line in fiscal 2025, bringing in $2.94M of $4.90M (60%).
| Health Care Organization, Revenue Sources | FY 2025 |
|---|---|
| Commercial Insurance | $2.94M |
| Self-Pay | $1.23M |
| Medicare | $724.00K |
| Total | $4.90M |
NRX Pharmaceuticals brought in $4.90M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. Commercial Insurance was the largest at $2.94M (60.1%), ahead of Self-Pay at $1.23M (25.1%) and Medicare at $724.00K (14.8%).
NRX Pharmaceuticals (NRXP) reports its revenue by product and service and by health care organization, revenue sources. In fiscal 2025, Therapy was its largest product and service line, bringing in $3.42M (69.7% of the total), followed by Procedures at $1.48M (30.3%).
Therapy was NRX Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $3.42M, or 69.7% of the $4.90M total across its two product and service lines.
Commercial Insurance was NRX Pharmaceuticals' largest revenue line in fiscal 2025, bringing in $2.94M, or 60.1% of the $4.90M total across its three revenue lines.
Every figure comes from NRX Pharmaceuticals' annual financial filings, as reported. Each line keeps the name NRX Pharmaceuticals gives it, and years follow its fiscal calendar.
NRX Pharmaceuticals' revenue by product and service goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.